Holding(s) in Company - Correction

RNS Number : 5969H

e-Therapeutics plc

18 August 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Holding(s) in Company - Correction

18 August 2016, Oxford, UK: Earlier today the Company released a Holding(s) in Company announcement (RNS Number: 5557H) forwarding a form TR1 received from Malcolm Philip Young (the "Announcement").

The form TR1 incorrectly stated that the shareholding of Malcolm Philip Young increased by 3,209,614 ordinary shares on 17 August 2016, when in fact Professor Young's shareholding increased by 3,350,228 ordinary shares on 6 June 2016, as previously announced by the Company on 7 June 2016.

Professor Young's current shareholding of 23,854,572 ordinary shares, representing 8.9% of the Company's issued share capital, was correctly stated in the Announcement.

- Ends -

Contacts:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk .  

 

END

 

 

HOLAKFDKABKDPFD